Research Associate II or III, Analytical Development (Cell Based & Immunoassays)
- Employer
- Precision BioSciences, Inc.
- Location
- Durham, NC
- Start date
- May 6, 2022
View more
- Discipline
- Information Technology, Business/Data Analytics, Regulatory
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Bio NC, Best Places to Work
Job Details
Summary
Precision BioSciences is seeking a Research Associate II or III whose primary focus will be to execute cell based and molecular assays within the Product Sciences Team. This person will provide bioanalytical support for Process Science projects related to manufacturing of cell therapy (CAR-T cell) products, adeno-associated virus (AAV) and mRNA. The Research Associate will participate in assay development, assay validation and technology transfer to quality control laboratories within Precision BioSciences. The position is lab-based with a focus on molecular biology and cell-based assays.
**Please note, Precision BioSciences mandates COVID-19 vaccination of all employees. Accommodations may be made in accordance with applicable law.
Essential Duties and Responsibilities
Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.
- Execute established assays and analyze data according to SOPs and report results of analysis in a timely manner
- Work individually and as part of a team to establish new assays that may be used for release of drug products or drug substance intermediates.
- Plate-based molecular and cell-based assay execution and analysis. Perform aseptic cell culture with primary mammalian cells or cell lines
- Participate in analytical assay validation and assay transfer exercises
- Coordinate with Process Sciences team to plan and conduct experiments that need to be carried out in a timely manner to achieve development goals
- Work individually and as part of a team to establish new assays that may be used for release of drug products or drug substance intermediates.
- Maintain an electronic lab notebook to document all experiments in a timely fashion
- Work collaboratively on aspects of experiments to be performed by other members of the team as part of larger ongoing experiments
- Coordinate with group leaders to ensure the following:
Qualifications
The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.
Required:
- BS degree in cell & molecular biology, immunology or related field and 2+ years of related biopharmaceutical industry experience and/or training, or MS in cell & molecular biology, immunology, or related field; or equivalent education and training
Preferred:
- Experience culturing primary human T cell and mammalian cell lines
- Experience in handling and analysis of large molecule biotherapeutics, cells, and nucleic acids
- Experience with molecular assays (ELISA, PCR) and cell-based assays (ADCC, Potency assays)
- Proficiency with plate readers and associated analysis software (e.g., SoftMax Pro, PLA)and Microsoft office applications
- Excellent collaboration and communication skills
- Familiarity with drug substance and drug product release testing methodologies
- Familiarity with statistical and DoE software (e.g., GraphPad Prism, JMP, etc.)
Location
Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com
Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
Company
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
- Website
- http://www.precisionbiosciences.com/
- Phone
- 919-314-5512
- Location
-
302 East Pettigrew Street
Durham
North Carolina
27701
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert